Gonadorelin

Author:Prof. Dr. med. Peter Altmeyer

All authors of this article

Last updated on: 29.10.2020

Dieser Artikel auf Deutsch

Synonym(s)

Gonadorelini acetas PhEur, gonadorelin acetate; Gonadorelinum, gonadoliberess

Requires free registration (medical professionals only)

Please login to access all articles, images, and functions.

Our content is available exclusively to medical professionals. If you have already registered, please login. If you haven't, you can register for free (medical professionals only).


Requires free registration (medical professionals only)

Please complete your registration to access all articles and images.

To gain access, you must complete your registration. You either haven't confirmed your e-mail address or we still need proof that you are a member of the medical profession.

Finish your registration now

DefinitionThis section has been translated automatically.

Gondaorelin is the natural releasing hormone of the hypothalamus, which stimulates the release of the two gonadotropins follitropin(FSH) and lutropin(LH) from the anterior pituitary gland by activating G-protein-dependent membrane receptors (GnRH receptors). Pharmacologically, native gonadorelin (gonadoliberin) is a basic decapeptide with a hairpin-shaped secondary structure.

The synthetic gonadorelin analogue triptorelin differs from gonadorelin only in the replacement of glycine in position 6 by D-Trp. Leuporelin and buserelin are nonapeptides with D-Leu and tert-butyl-D-Ser respectively, in which the C-terminal glyconamide is additionally replaced by an ethylamino group.

The synthetic gonadorelin analogues have a considerably higher intrinsic activity towards the GnRH receptor (so-called superagonists). They suppress gonadotropin release after transient, initial stimulation by downregulation of the pituitary GnRH receptors.

Note(s)This section has been translated automatically.

The competitive synthetic gonadorelin receptor antagonists Cetorelix and Ganirelix are decapeptides in which several positions of native gonadorelin are substituted with C-amino acids. They directly inhibit gonadotropin secretion without initial stimulation. The preparations Abarelix and Degarelix are approved for the therapy of prostate carcinoma.

Authors

Last updated on: 29.10.2020